$ALKS

Gaffin David Joseph sold $110K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $54.03 ($0.11M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Jul 6, 2026, 8:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The newest disclosed fact is the same-day open-market sale of 2,034 shares by an EVP at a stated price, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information to drive a directional trade.

03

What to watch

The article lacks context on total planned sales, prior insider activity cadence, and whether the sale was part of a larger scheduled program; without that, signal strength is limited.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-06 (after-hours) for an insider sale executed the same day.

Background

This is a SEC Form 4 insider transaction filed via EDGAR for Alkermes plc (ALKS).

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes EVP David Joseph Gaffin filed a Form 4 selling 2,034 shares at $54.03 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory news disclosed.

Market effects

No clear read-across to the biotech/pharma sector because the disclosure is a planned insider transaction without new company fundamentals.

Minimal; this is a single-company insider sale with no broader market linkage stated.

Low; no international deal, regulator action, or supply-chain event is mentioned.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be watched as a sentiment check, especially if it coincides with other negative signals not present here.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider transaction; EVP David Joseph Gaffin sold shares under a 10b5-1 plan.

  • David Joseph Gaffin

    EVP, CLO at Alkermes; reported open-market sale of 2,034 shares at $54.03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.